What the FDA labels say about taking them together
Celecoxib and heparin
Heparin's FDA label (Heparin Sodium) of April 30, 2026 names celecoxib in its drug interactions section; celecoxib's label does not name heparin itself but warns about its class (anti-coagulants). The heparin label: “Drugs such as NSAIDS, dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIv/IIa antagonists, and others that interfere with platelet-aggregation reactions may induce bleeding and …”
Check it at the source: the celecoxib FDA label on DailyMed (effective November 22, 2024, Viatris Specialty LLC); the heparin FDA label on DailyMed (effective November 28, 2025, Fresenius Kabi USA, LLC).
What does the celecoxib label say about heparin?
Celecoxib's label does not name heparin itself; it warns about its class (anti-coagulants):
Celecoxib label, drug interactionsCelecoxib and anticoagulants such as warfarin have a synergistic effect on bleeding.
Celecoxib label, drug interactionsThe concomitant use of Celecoxib and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone.
Source: FDA drug label (CELEBREX), NDA020998 (Upjohn), as published by Viatris Specialty LLC, effective November 22, 2024 (SPL set 2d6675e4-5859-4be2-8037-a20ce9f707aa), via openFDA; the full label on DailyMed
What does the heparin label say about celecoxib?
Heparin Sodium label (Fresenius Kabi USA, LLC, April 30, 2026), drug interactionsDrugs such as NSAIDS (including salicylic acid, ibuprofen, indomethacin, and celecoxib), dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIb/IIIa antagonists (including abciximab, eptifibatide, and tirofiban), and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
Source: FDA drug label (Heparin Sodium, NDA017029), Fresenius Kabi USA, LLC, effective April 30, 2026 (SPL set 2a173253-dfdc-4d9d-8dee-b9c13e6fa9f5), via openFDA
Source: FDA drug label (Heparin Sodium In Sodium Chloride, NDA018609), Baxter Healthcare Corporation, effective January 3, 2022 (SPL set 0d929726-76c3-48fc-b4e7-fd06409f9fb3), via openFDA
Source: FDA drug label (Heparin Sodium), Fresenius Kabi USA, LLC, effective November 28, 2025 (SPL set d55b4a63-0c04-4874-b74f-9e9b9e8b008c), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Celecoxib | Heparin | |
|---|---|---|
| Labeled for | Osteoarthritis, Rheumatoid arthritis, Pain, Migraine | Blood clots (DVT and PE), Atrial fibrillation |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.0762 per capsule 200 mg capsule | $1.18 per mL 5,000 unit/mL vial |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once